Drug intelligence / Profile preview

ANB102

Development stage: Preclinical
Lead developer: AnaptysBio
Modality: Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ANB102 is an extended half-life monoclonal antibody that acts as a BDCA2 modulator, specifically targeting the C-type lectin domain family 4 member C (BDCA2) on plasmacytoid dendritic cells. By modulating BDCA2, ANB102 aims to inhibit interferon secretion and antigen presentation, processes implicated in the pathogenesis of systemic autoimmune and inflammatory diseases. The drug is designed for less frequent dosing (potentially quarterly or less), which may improve patient compliance. Originally developed by Centessa Pharmaceuticals, ANB102 was licensed to AnaptysBio in late 2023 for further development in autoimmune and inflammatory indications[1][7][8].

Targets

CLEC4C (C-type lectin domain family 4 member C)

Beyond the preview

Go deeper on ANB102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANB102.

Explore the full profile